73 related articles for article (PubMed ID: 22771790)
1. HDACI-induced thrombocytopenia is caused by its unexpected target.
Kitamura T; Inoue D
Exp Hematol; 2012 Sep; 40(9):695-7. PubMed ID: 22771790
[No Abstract] [Full Text] [Related]
2. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.
Iancu-Rubin C; Gajzer D; Mosoyan G; Feller F; Mascarenhas J; Hoffman R
Exp Hematol; 2012 Jul; 40(7):564-74. PubMed ID: 22381681
[TBL] [Abstract][Full Text] [Related]
3. Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.
Messaoudi K; Ali A; Ishaq R; Palazzo A; Sliwa D; Bluteau O; Souquère S; Muller D; Diop KM; Rameau P; Lapierre V; Marolleau JP; Matthias P; Godin I; Pierron G; Thomas SG; Watson SP; Droin N; Vainchenker W; Plo I; Raslova H; Debili N
Nat Commun; 2017 Nov; 8(1):1786. PubMed ID: 29176689
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide.
Bishton MJ; Gardiner EE; Harrison SJ; Prince HM; Johnstone RW
Thromb Res; 2013 Jun; 131(6):514-20. PubMed ID: 23642854
[TBL] [Abstract][Full Text] [Related]
5. Compounds targeting class II histone deacetylases do not cause panHDACI-associated impairment of megakaryocyte differentiation.
Simic D; Sang N
Exp Hematol; 2019 Apr; 72():36-46. PubMed ID: 30611870
[TBL] [Abstract][Full Text] [Related]
6. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes.
Giver CR; Jaye DL; Waller EK; Kaufman JL; Lonial S
Leukemia; 2011 Feb; 25(2):362-5. PubMed ID: 21109772
[No Abstract] [Full Text] [Related]
7. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of HDAC inhibitor-induced thrombocytopenia.
Matsuoka H; Unami A; Fujimura T; Noto T; Takata Y; Yoshizawa K; Mori H; Aramori I; Mutoh S
Eur J Pharmacol; 2007 Oct; 571(2-3):88-96. PubMed ID: 17628529
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.
Bishton MJ; Harrison SJ; Martin BP; McLaughlin N; James C; Josefsson EC; Henley KJ; Kile BT; Prince HM; Johnstone RW
Blood; 2011 Mar; 117(13):3658-68. PubMed ID: 21292776
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
11. SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic stem cells.
Toscano MG; Navarro-Montero O; Ayllon V; Ramos-Mejia V; Guerrero-Carreno X; Bueno C; Romero T; Lamolda M; Cobo M; Martin F; Menendez P; Real PJ
Mol Ther; 2015 Jan; 23(1):158-70. PubMed ID: 25292191
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells.
Francisco R; Pérez-Perarnau A; Cortés C; Gil J; Tauler A; Ambrosio S
Cancer Lett; 2012 May; 318(1):42-52. PubMed ID: 22186300
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
14. Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.
Ali A; Bluteau O; Messaoudi K; Palazzo A; Boukour S; Lordier L; Lecluse Y; Rameau P; Kraus-Berthier L; Jacquet-Bescond A; Lelièvre H; Depil S; Dessen P; Solary E; Raslova H; Vainchenker W; Plo I; Debili N
Cell Death Dis; 2013 Jul; 4(7):e738. PubMed ID: 23887629
[TBL] [Abstract][Full Text] [Related]
15. [Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells].
Yang YN; Wang Y; Wang XG; Jiang SJ
Ai Zheng; 2008 Aug; 27(8):816-21. PubMed ID: 18710614
[TBL] [Abstract][Full Text] [Related]
16. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
[TBL] [Abstract][Full Text] [Related]
17. Manipulation of B-cell responses with histone deacetylase inhibitors.
Waibel M; Christiansen AJ; Hibbs ML; Shortt J; Jones SA; Simpson I; Light A; O'Donnell K; Morand EF; Tarlinton DM; Johnstone RW; Hawkins ED
Nat Commun; 2015 Apr; 6():6838. PubMed ID: 25913720
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Sanchez E; Shen J; Steinberg J; Li M; Wang C; Bonavida B; Chen H; Li ZW; Berenson JR
Leuk Res; 2011 Mar; 35(3):373-9. PubMed ID: 20650529
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors that target tubulin.
Schemies J; Sippl W; Jung M
Cancer Lett; 2009 Aug; 280(2):222-32. PubMed ID: 19268440
[TBL] [Abstract][Full Text] [Related]
20. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
